BioAge

Deadline Approaches for BioAge Labs Investors to Join Securities Fraud Lawsuit Following Failed Clinical Trial

by

SAN DIEGO — Robbins Geller Rudman & Dowd LLP, a prominent law firm, has issued an announcement regarding a class action lawsuit against BioAge Labs, Inc., urging investors to come forward if they were affected by the company’s recent IPO issues. Shareholders who acquired stock in BioAge Labs (NASDAQ: BIOA) during its initial public offering on September 26, 2024, or based on the related registration statement, are invited to seek a lead plaintiff position in the lawsuit by the impending deadline of March 10, 2025. The lawsuit, officially known as Soto v. BioAge Labs, Inc., … Read more

Bleichmar Fonti & Auld LLP Files Lawsuit Against BioAge Labs Over Alleged IPO Misrepresentations, Urges Investors to Join Legal Action

by

NEW YORK — Legal actions have commenced against BioAge Labs, Inc., a clinical-stage biopharmaceutical company known for its advanced therapies aimed at metabolic diseases like obesity. A lawsuit filed in the U.S. District Court for the Northern District of California accuses BioAge and some of its top executives of potential breaches of federal securities laws. The securities law firm Bleichmar Fonti & Auld LLP, leading the litigations, announced these proceedings detailing that the lawsuit encapsulates claims under Sections 11 and 15 of the Securities Act of 1933. The complaint specifically represents investors who acquired shares … Read more

Investor Lawsuit Targets BioAge Labs Following Disrupted Drug Trial and Stock Plunge

by

New York — A prominent securities law firm, Bleichmar Fonti & Auld LLP, has recently initiated a lawsuit against BioAge Labs, Inc., a company listed on NASDAQ under the ticker BIOA, along with some of its top executives. The legal action alleges potential breaches of federal securities laws linked to the company’s initial public offering. As part of the case, which is filed under the docket Soto v. BioAge Labs, Inc., et al., No. 25-cv-196, plaintiffs must file their petitions by March 10, 2025, to be considered as lead plaintiffs. The filed complaint highlights issues … Read more

Opportunity Opens for BIOA Investors to Lead in BioAge Labs Securities Fraud Case with Schall Law Firm Support

by

Los Angeles, CA – Investors who have placed their funds in BioAge Labs, Inc. shares are being invited to potentially lead a class action lawsuit alleging securities fraud, with legal support from the Schall Law Firm. This development follows claims that the biotechnology company may have violated securities laws, possibly impacting investor trust and financial losses. The lawsuit centers on accusations that BioAge Labs raised investor expectations with purportedly misleading statements about its business prospects and operations. Among the concerns raised are issues related to the public disclosures made by the company, which allegedly provided … Read more